ERBB2 and breast carcinoma: Relevance to the human disease is underlined by the findings that PGC-1α expression is positively correlated with that of the glutamine pathway in ERBB2+ breast cancer patients, and that high expression of the glutamine pathway is associated with shorter survival time.